Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges) LoginRegister
Psoriasis Club is a friendly on-line Forum where people with psoriasis or psoriatic arthritis
can get together and share information, get the latest news, or just chill out with others who understand. It is totally
self funded and we don't rely on drug manufacturers or donations. We are proactive against Spammers,
Trolls, And Cyberbulying and offer a safe friendly atmosphere for our members.
So Who Joins Psoriasis Club?
We have members who have had psoriasis for years and some that are newly diagnosed. Family and friends of those with psoriasis
are also made welcome. You will find some using prescribed treatments and some using the natural approach. There are people who
join but keep a low profile, there are people who just like to help others, and there are some who just like
to escape in the Off Topic Section.
Joining Couldn't Be Easier: If you are a genuine person who would like to meet others who understand,
just hit the Register button and follow the instructions.
Members get more boards and privileges that are not available to guests.
OK So What Is Psoriasis?
Psoriasis is a chronic, autoimmune disease that appears on the skin. It
occurs when the immune system sends out faulty signals that speed up the
growth cycle of skin cells. Psoriasis is not contagious. It commonly
causes red, scaly patches to appear on the skin, although some patients
have no dermatological symptoms. The scaly patches commonly caused by
psoriasis, called psoriatic plaques, are areas of inflammation and
excessive skin production. Skin rapidly accumulates at these sites which
gives it a silvery-white appearance. Plaques frequently occur on the
skin of the elbows and knees, but can affect any area including the
scalp, palms of hands and soles of feet, and genitals. In contrast to
eczema, psoriasis is more likely to be found on the outer side of the
joint.
The disorder is a chronic recurring condition that varies in severity
from minor localized patches to complete body coverage. Fingernails and
toenails are frequently affected (psoriatic nail dystrophy) and can be
seen as an isolated symptom. Psoriasis can also cause inflammation of
the joints, which is known as (psoriatic arthritis). Ten to fifteen
percent of people with psoriasis have psoriatic arthritis.
The cause of psoriasis is not fully understood, but it is believed to
have a genetic component and local psoriatic changes can be triggered by
an injury to the skin known as Koebner phenomenon. Various
environmental factors have been suggested as aggravating to psoriasis
including stress, withdrawal of systemic corticosteroid, excessive
alcohol consumption, and smoking but few have shown statistical
significance. There are many treatments available, but because of its
chronic recurrent nature psoriasis is a challenge to treat. You can find more information
Here!
Got It, So What's The Cure?
Wait Let me stop you there! I'm sorry but there is no cure. There are things that can help you
cope with it but for a cure, you will not find one.
You will always be looking for one, and that is part of the problem with psoriasis There are people who know you will be
desperate to find a cure, and they will tell you exactly what you want to hear in order to get your money. If there is a
cure then a genuine person who has ever suffered with psoriasis would give you the information for free. Most so called cures
are nothing more than a diet and lifestyle change or a very expensive moisturiser. Check out the threads in
Natural Treatments first and save your money.
Great so now what? It's not all bad news, come and join others at Psoriasis Club and talk about it. The best help is from accepting it and talking
with others who understand what you're going through. ask questions read through the threads on here and start claiming
your life back. You should also get yourself an appointment with a dermatologist who will help you find something that can
help you cope with it. What works for some may not work for others
Hello all, I've, got Graves' disease, which has given me plaque psoriasis, and when I'm over active, I need help keeping my psoriasis under control by the use of acitretin, but I dont like the same de affects, also it doesn't clear my scalp, so I was looking for any advise, on what to use on my scalp, thank you
hello I am Deena. I'm 45 years, female, and a mommy of a son and a daughter. i have been diagnosted of artritis psoriatica when I was 16 years. Sinds September 2014 I use Psorinovo and reishi/ganoderma capsules. sinds december 2014 I'm clean of psoriasis. thanks to the psorinovo. ohw I am from Holland and I came to this forum, because in Dutch there are not much forums abouth psoriasis who are up to date, and the one there is you have to become a paying member, and that one is also not much in use. I hope there are more confersations going on here. and I hope to share experiences here.
Hi all. I've been dealing with this flipping rash for about five years now. First person to see it declared it ringworm (one lesion was a classic ring shape). Second person called it eczema. Five years, five doctors and two herbalists later, and I'm told it's psoriasis. This was a couple of weeks ago.
Hoo boy. Talk about a club I never wanted to join.
I just woke up one morning covered in it (including my special, tinder sittin' down place), but it quickly resolved itself to two symmetrical bands around my ankles. Not too awful, except when it flares up...then my shoes cut into it and walking is painful.
So my first priority is learning what triggers flare-ups, so I can stop doing...whatever it is. That's the problem; I really haven't a clue.
I'll do a lot of reading and hope there's stuff here already to give me ideas. But my name will be hovering around, so I thought I should introduce myself.
So, hello from the sunny South coast of England. Where it's snowing a little.
Posted by: Fred - Tue-03-02-2015, 10:55 AM
- No Replies
This small study ahead of publication suggests granulysin may be a potential target for immunomodulatory therapy for psoriasis.
Quote:Background:
Psoriasis is an erythematosquamous dermatosis, which has strong expression of antimicrobial peptides (AMPs), imparting a high resistance to lesional skin infection. Granulysin is a proinflammatory AMP that has been found in some infection-resistant dermatoses.
Aim:
To assess granulysin expression in psoriasis.
Methods:
Immunohistochemical expression of granulysin was assessed in lesional skin biopsies taken from 30 patients with psoriasis and 10 normal skin specimens from healthy controls (HCs) matched for age, gender and skin site. Granulysin expression was found to be high in 11 patients (36.7%), moderate in 10 (33.3%) and low in 9 (30%). A highly significant (P = 0.001) difference in granulysin expression between patients with psoriasis and HCs was found. There were also significant differences in granulysin expression between patients with low Psoriasis Area and Severity Index (PASI) (≤ 10) and those with high PASI (> 10) (P = 0.001), and between patients with early-onset (< 40 years of age) and those with late-onset (> 40 years of age) disease (P < 0.04). There was a significant (P = 0.001) positive correlation between granulysin expression and PASI (r = 0.84) and a significant (P = 0.02) negative correlation with age of onset (r = −0.38). Patients with psoriasis hadhigh granulysin expression, which increased with increased clinical severity of the disease.
Conclusions:
These findings suggest a role for granulysin in psoriasis pathogenesis, and may explain the triggering effect of skin infection in psoriasis. If the pathogenic role of granulysin is substantiated by further studies, granulysin may be a potential target for immunomodulatory therapy for psoriasis.
Source: onlinelibrary.wiley.com
Author Information:
Department of Dermatology and Venereology and , Tanta University, Tanta, Egypt
Department of Pathology, Tanta University, Tanta, Egypt
Department of Dermatology, Om-El-Masryeen Hospital, Cairo, Egypt
Posted by: Fred - Sat-31-01-2015, 12:11 PM
- No Replies
This is an early view of a descriptive study that the authors hope may serve to inspire a more mechanistic approach exploring not only Wnt5a, but other inflammatory pathways in between the skin and the fat.
Quote:
Substantial epidemiological evidence indicates that psoriasis associates with a predisposition to develop metabolic dysregulation leading to obesity and insulin resistance. However, the nature of this association and the potential underlying mechanisms remain unclear.
In a recent report, Gerdes et al. explored the hypothesis that wingless-type MMTV integration site, Wnt5a, which has been linked to aberrant fat cell metabolism, may be driving this process. In this study, the authors compare circulating serum levels of Wnt5a in individuals with psoriasis and compare with healthy controls matched for age, gender and BMI.
The bottom-line results show higher levels of Wnt5a in psoriasis patients irrespective of BMI compared to the matched non-psoriatic controls, indicating that psoriasis per se may result in increased secretion of Wnt5a into the circulation. In addition, there was a significant difference among patients with higher levels of Wnt5a in the obese psoriasis population.
The study, even though being purely descriptive, may serve to inspire a more mechanistic approach exploring not only Wnt5a, but other inflammatory pathways in between the skin and the fat.
Source: onlinelibrary.wiley.com
Dermatology and Venereology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Posted by: Fred - Sat-31-01-2015, 12:10 PM
- Replies (1)
This article looked at the digital phototherapy device Skintrek and concluded it is as effective as conventional cream and bath PUVA, as well as NB-UVB, while simultaneously sparing the healthy adjacent skin.
Quote:Background:
8-Methoxypsoralen–UVA (PUVA) and narrowband ultraviolet B (NB-UVB) are well-established treatments for chronic plaque-type psoriasis vulgaris. However, long-term risks of PUVA therapy include premature skin ageing and squamous cell carcinoma.
Objectives:
To develop a device for targeted UV therapy of psoriatic plaques with protection of the healthy adjacent skin to reduce the risk for premature skin ageing and squamous cell carcinoma.
Methods:
In total 28 patients with exacerbated psoriasis vulgaris were treated with the digital phototherapy device skintrek® [cream PUVA (n = 8), bath PUVA (n = 11) and UVB (n = 9)] or with conventional bath PUVA (n = 9) or NB-UVB (n = 4).
Results:
The local Psoriasis Area and Severity Index (PASI) score was significantly reduced from a mean of 6·25 at baseline to 2·75 at the end of therapy in the skintrek cream PUVA group, from 6·4 to 3·0 in the skintrek bath PUVA group and from 5·5 to 2·0 in the skintrek UVB group. Treatment with skintrek cream PUVA reduced the mean local PASI by 54%, while skintrek bath PUVA did so by 51% and skintrek UVB by 63%. Targeted skintrek PUVA and skintrek UVB of inflamed psoriatic skin avoided skin pigmentation and were not inferior to conventional bath PUVA and NB-UVB therapy regimens.
Conclusions:
Targeted UV therapy of psoriatic plaques with the digital phototherapy device skintrek is as effective as conventional cream and bath PUVA, as well as NB-UVB, while simultaneously sparing the healthy adjacent skin. It therefore potentially reduces the carcinogenic risk, reduces premature skin ageing and avoids tanning of healthy surrounding skin.
Source: onlinelibrary.wiley.com
Funding: This study was supported by the German Federal Ministry of Economics and Technology (Zentrales Innovationsprogramm Mittelstand).
Posted by: Fred - Sat-31-01-2015, 12:09 PM
- No Replies
This is an early view of a 10 patients study in the use of combination psoriasis treatments Cyclosporine and anti-TNF α.
Quote:
Combination therapy has become important in treating psoriasis, using synergism between different mechanisms to maximize efficacy and minimize toxicity. Little has been published on the combination of cyclosporine and anti-tumor necrosis factor (TNF) α agents.
In this study, a retrospective chart review was made of the effects of this combination therapy in 10 patients with recalcitrant psoriasis.
Treatment included a conditioning phase with cyclosporine, 3.14 ± 0.37 mg/kg for 4.6 ± 2 weeks, and a combination phase during which etanercept/adalimumab were initiated and cyclosporine was tapered over 10.2 ± 3.7 weeks.
Treatment success, evaluated after each phase, was classified as complete recovery (CR, more than 75% improvement), partial response (PR, 25–75% improvement), and no response (NR, less than 25% improvement). All patients reached CR at the end of the combination therapy. Two were still on combination therapy after 12 and 20 weeks. Adverse event occurred in three cases, all in the conditioning phase.
We conclude that combination therapy with cyclosporine and anti-TNF α appears to offer an effective and safe approach to treatment of psoriasis.
Posted by: Fred - Sat-31-01-2015, 12:07 PM
- Replies (2)
This study looked at the cost efficacy of systemic psoriasis treatments approved for use by the US Food and Drug Administration (FDA).
Quote:Background:
Newer psoriasis treatments tout higher efficacy but are generally more expensive.
Objective:
We sought to estimate the cost efficacy of systemic psoriasis treatments that have been approved by the US Food and Drug Administration (FDA).
Methods:
A literature review of systemic psoriasis treatments that have been approved by the FDA was performed for the primary end point of a 75% reduction in the Psoriasis Area and Severity Index score (PASI 75). Medication cost was referenced by wholesale acquisition cost (WAC), laboratory fees were obtained from the American Medical Association, and office visit fees are standard at our university. Total expenses were standardized by calculating cost per month of treatment considering the number needed to treat (NNT) to achieve PASI 75.
Results:
Methotrexate ($794.05-1502.51) and cyclosporine ($1410.14-1843.55) had the lowest monthly costs per NNT to achieve PASI 75. The most costly therapies were infliximab ($8704.68-15,235.52) and ustekinumab 90 mg ($12,505.26-14,256.75). Monthly costs per NNT to achieve PASI 75 for other therapies were as follows: narrowband ultraviolet B light phototherapy ($2924.73), adalimumab ($3974.61-7678.78), acitretin ($4137.71-14,148.53), ustekinumab 45 mg ($7177.89-7263.99), psoralen plus ultraviolet A light phototherapy ($7499.46-8834.98), and etanercept ($8284.71-10,674.89).
Limitations:
Drug rebates and incentives, potential adverse effects, comorbidity risk reduction, ambassador programs, and combination therapies were excluded.
Conclusion:
Our study provides meaningful cost efficacy data that may influence psoriasis treatment selection.
Hi everyone, newbie to the board. Im 31 had psoriasis since age 10 recently dx with ms...clearly this complicates things. My neurologist wants me to start tecfidera, im from US btw. I an hoping it will help my p. I have googled and googled and cant find anything. I called biogen and asked them if tecfidera has helped pts with p and they said no studies have shown that. In any event i am starting and hopeful the main ingredient dmf will help my p as well as ms. What is the clearing like. From what i understand it takes a while? Thoughts and comments woyld be appreciated thank you so much. Also, could you be on another drug like stelara and tecfidera? Jw with incidence of pml.
Posted by: Fred - Wed-28-01-2015, 17:14 PM
- Replies (2)
Lot's of Biosimilars coming through lately for well known psoriasis treatments, and today Samsung Bioepis announced that their Enbrel (etanercept) biosimilar candidate, SB4 has been validated and accepted for review by European Medicines Agency (EMA)
Quote:
Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for its Enbrel (etanercept) biosimilar candidate, SB4 has been validated and accepted for review by European Medicines Agency (EMA). The acceptance of the MAA marks the first Enbrel biosimilar to advance into regulatory review in the European Union (EU). The MAA is based on results from a Phase III clinical trial in patients with moderate-to-severe rheumatoid arthritis (RA).
In Europe, Enbrel is indicated for the treatment of a number of rheumatic diseases, including moderate to severe RA, certain forms of juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. If authorized by the EMA, SB4 could be available for use in all of the same indications as Enbrel.
"This MAA validation represents a significant milestone for Samsung Bioepis in our work to develop and manufacture world-class biosimilars. More significantly, it offers an opportunity to provide high-quality and effective therapies for broadening access to patients in Europe" said Christopher Hansung Ko, chief executive officer of Samsung Bioepis.
If authorized by the EMA, SB4 will be commercialized in Europe by Biogen Idec. It will also be produced at the company’s manufacturing facility in Hillerød, Denmark which is one of the largest biologic manufacturing facilities in the world.
In addition to the European filings, Samsung Bioepis intends to move forward with additional applications for regulatory approvals in other territories worldwide.
About the SB4
Samsung Bioepis previously conducted SB4 Phase 1 and Phase 3 clinical studies. The MAA for the etanercept biosimilar was based on data from a Phase 3, controlled, randomized, multicenter study in Europe where SB4 demonstrated its comparability to Enbrel®. The primary and secondary endpoints of the study were assessed and met the qualification standard for the MAA submission. Full data from the study will be available later this year.
Hi all, just joined the forum! Have been reading some of the posts and just have a question I hope ye can help me with. Just started fumaderm this month. My dermatologist has only given me a one month prescription and has then requested for me to see him again one month in. Can anyone tell me if I need to see him every month for a check up and my prescription or will I eventually get to start seeing him less?? Thanks
Posted by: Fred - Tue-27-01-2015, 23:32 PM
- Replies (3)
Who's the better judge to know how a psoriatic patient is feeling? Is it the patient or the physician? This study set out to try and work it out. What do you think, do you know better than your physician? (I know I do I have the bloody psoriatic arthritis they don't.)
Quote: Objective:
To assess the extent and determinants of discordance in scoring between patient global assessment (PtGA) and physician global assessment (PhGA) in patients with psoriatic arthritis (PsA).
Methods:
A cross-sectional and longitudinal analysis of data was conducted in patients attending a large PsA clinic. The difference between PtGA and PhGA (each measured on a scale of 0–10, with 0 indicating best status and 10 indicating worst status) reflected the discrepancy between the PtGA and PhGA of joint and skin activity and could take values from −10 (higher rating of disease activity by the patient) to 10 (higher rating of disease activity by the physician). Multivariate regression identified variables that contributed significantly to each of the outcomes. The proportion of variability of each outcome explained by each predictor was expressed by the partial R2.
Results:
A total of 565 patients were included in the analysis. Patients tended to score their disease worse than their physicians, with greater discordance for the joints than for the skin (mean ± SD 1.68 ± 2.41 PtGA–PhGA difference for joints, and 0.77 ± 2.66 for skin). Fatigue accounted for 21% of the variation in the difference between PtGA and PhGA for joints. Pain (inline image = 9%) and disability by Short Form 36 health survey (inline image = 1.2%) were also important factors, each of which led to higher patient rating; whereas increased tender joint count (inline image = 16%) and swollen joint count (inline image = 1.4%) resulted in a higher physician rating of arthritis.
Conclusion:
Fatigue, pain, disability, and tender and swollen joint counts were the most important factors contributing to discrepancy between patient and physician assessment of joint activity.
Source: NO LINKS ALLOWED
Funded by: The Arthritis Society, Canadian Institutes of Health Research, Krembil Foundation, Canadian Institutes of Health Research Fellowship, Canadian Institutes of Health Research Clinical Research Initiative Fellowship
Posted by: Fred - Tue-27-01-2015, 09:33 AM
- Replies (11)
I'm always saying a positive attitude is a huge benefit to those of us with psoriasis (struggling myself at the moment, but that's another story) and I found this small study interesting in that it suggests *Type D personality is higher in patients with moderate to severe psoriasis as compared to healthy volunteers.
*Individuals with a Type D personality have the tendency to experience increased negative emotions across time and situations and tend not to share these emotions with others, because of fear of rejection or disapproval.
Quote:Background:
Psoriasis may imply a remarkable psychological impairment, which can influence patient's personality. The Type D personality is defined by the combination of social inhibition and negative affectivity. Furthermore, Type D personality has been associated with impaired health-related quality of life (HRQOL) and increased cardiovascular risk, both facts being associated with moderate to severe psoriasis.
Objectives:
To explore the prevalence of Type D personality in moderate to severe psoriasis patients; To analyse the relationship between Type D personality and the most common physical and psychological comorbidities in moderate to severe psoriasis and To explore the impact of Type D personality on HRQOL.
Methods:
A prospective comparative study matched to age and sex. Eighty patients with moderate to severe psoriasis and 80 healthy volunteers were included in the study. The participants completed the DS14 test, the Massachusetts General Hospital-Sexual Functioning Questionnaire, the Hospital Anxiety and Depression Scale, the SF-36 and the Psoriasis Disability Index.
Results:
The prevalence of Type D personality was higher in patients with moderate to severe psoriasis as compared to healthy volunteers: 38.7% vs. 23.7%, P < 0.001. Psoriasis patients with Type D personality had a 3.2-fold risk of anxiety when compared to patients without Type D personality; odds ratio 3.2 (1.3–8.83 P = 0.01). Type D personality was significantly associated with an impaired general, sexual and psoriasis-related HRQOL (P < 0.01).
Conclusion:
Because Type D personality could represent a frequent type of personality among individuals with moderate to severe psoriasis, it could serve as a ‘marker’ of more psychologically vulnerable patients, probably related to dysfunctional coping strategies. The Type D personality could represent a profile more frequently encountered among patients with psoriasis, and might therefore help identify subjects physiologically more vulnerable to disease, most likely due to inadequate adaptation mechanisms.
Hi my name is lisa.
I am 32 years old and have suffered from plaque and guttate psoriasis since I was 16.
It had recently gotten very bad following an allergic reaction I had to washing powder. I was literally burning on the outside with a good 50% of my body being covered in what felt like sunburn. I was immediately sent to my dermatologist who advised the use of methotrexate tablets 10mg with folic acid weekly. I was a little hesitant at first as the list of symptoms was both long and fairly in depth. I did however after 3 months of pure misery decide to give it a go. I literally couldn't get dressed it had gotten that bad. Everything that I put on burned, diet didn't help, even the topical treatments I had been using for years to control it had failed. I couldn't bathe or shower, I didn't go out, I even stopped going to work. My children couldn't even hug me without me wincing in pain. It was horrific! So the tablets arrived and I started a low dose over a 10 week period gradually built up to 10mg strength. I can tell you all that this treatment has been a huge success. Within just 3 weeks I had noticed the itchy red raw patches were less itchy and not as painful, my skin resisted cracking and flaking as much. It's steadily gotten better and better and 12 weeks in it is gone from my scalp, arms and if faiding on my torso and legs. I am amazed. I am over the moon. My life has come back to me. I can only hope the healing continues in the coming months. Very few side affects. Dry mouth and preety constant headache but that's a very very small price to pay.........
Posted by: jbcm8 - Fri-23-01-2015, 07:02 AM
- Replies (21)
Hello all. I am Michelle vuong. I have been suffering plaque sporisasis for about 6 years. About 6 months ago, I was at my doctor office waiting to see the doctor and scratching my knee cap at the same time. A health educator saw me and told me to use duct tape. I was like " realy", why not?? And 6 month later the 24 hour itchiness is practically gone, the skin is back to normal except there is a white patch where the plaque is used to be. So far the duct tape works for me. May be someone on this site might want to try it. Good luck.
There are no sigs that psoriasis could be viral.
However there are signs, that is research, that indicate that bacteria may be in involved.
There are also thoughts that psoriasis has to do with mitochondrial cells.
Posted by: RubyDots - Thu-22-01-2015, 03:01 AM
- Replies (3)
Hi fellow itchers! Has anyone here tried secukinamub or been in the trials? They just approved it in the US today so i thought i'd ask before I call my derm.
Posted by: Fred - Wed-21-01-2015, 21:45 PM
- Replies (3)
This study looked into the role of vitamin D in psoriasis, it is an early view before publication in The International Journal of Dermatology.
Quote:Background and objective:
Psoriasis is a common, chronic autoimmune inflammatory skin disorder, which has potential systemic complications and is clinically defined by sharply demarcated, erythematous patches and plaques covered by a characteristic silvery white scale. Topical corticosteroids have widely been regarded as the mainstay first line of treatment. Recently, topical vitamin D analogs have been added to the first-line treatment repertoire as well, either as monotherapy or in combination with topical steroids due to synergistic, complementary effectiveness. In this paper, we review the role of vitamin D in the pathophysiology and treatment of psoriasis.
Methods:
A comprehensive search of the Cochrane Library, MEDLINE, and pub med databases were performed to identify relevant basic science and clinical trial literature investigating the role of vitamin D in psoriasis. Primary endpoints in clinical trials were largely based on clinical improvement as assessed by the psoriasis area severity index score or physician's global assessment.
Results and conclusion:
The role of vitamin D in psoriasis is complex and extensive. Oral and topical vitamin D therapies provide comparable efficacies to corticosteroids when used as monotherapy and may be superior when used in combination with a potent topical steroid. Additionally topical vitamin D analogs demonstrate a favorable safety profile with “steroid-sparing” effects. Thus, topical vitamin D derivatives should be considered an indispensable component of the current physician's arsenal in the treatment of psoriasis.
Posted by: Fred - Wed-21-01-2015, 20:45 PM
- Replies (1)
US Food and Drug Administration (FDA) follow Japan and Europe and gives the go ahead for Cosentyx (secukinumab) to be used as a psoriasis treatment.
Quote:
Novartis today announced the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy). Cosentyx is the first approved psoriasis medication to selectively bind to IL-17A and inhibit interaction with the IL-17 receptor. The approval is based on the efficacy and safety outcomes from 10 Phase II and Phase III studies, including over 3,990 adult patients with moderate-to-severe plaque psoriasis, which demonstrated that Cosentyx resulted in clear or almost clear skin in the majority of patients and had an acceptable safety profile.
"The FDA's approval of Cosentyx signifies a turning point for psoriasis patients, who can now benefit from the first and only approved treatment targeting the IL-17 pathway, which is proven to play a key role in the development of plaque psoriasis," said David Epstein, Division Head, Novartis Pharmaceuticals. "This important milestone will now allow patients to receive a treatment that has the proven ability to offer clear or almost clear skin."
The FDA approval follows the unanimous vote by the FDA Advisory Committee in October 2014. Additionally, in January 2015, the European Commission (EC) approved Cosentyx as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
Affecting 7.5 million Americans and more than 125 million people worldwide, psoriasis is a chronic immune-mediated disease characterized by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain and may negatively impact daily life. Nearly 35% of psoriasis patients suffer from moderate-to-severe plaque psoriasis. Research shows IL-17A plays an important role in driving the body's immune response in disorders such as moderate-to-severe plaque psoriasis. Cosentyx selectively binds to IL-17A, inhibiting its activity.
The Phase III clinical program included four placebo-controlled studies which examined Cosentyx 300 mg and 150 mg in patients with moderate-to-severe plaque psoriasis. In these studies, Cosentyx met all primary and key secondary endpoints, including Psoriasis Area and Severity Index (PASI) 75 and 90 and Investigator's Global Assessment modified 2011 (IGA) 0/1 responses, showing significant skin clearance at Week 12. PASI measures the redness, scaling and thickness of psoriatic plaques, and the extent of involvement in each region of the body. Treatment efficacy is assessed by the reduction of the score from baseline (i.e. a 75% reduction is known as PASI 75 and a 90% reduction is known as PASI 90). PASI 90 is a higher standard of skin clearance compared to PASI 75.
Has anyone with psoriasis ever been told cats can have a very bad effect on your skin? I have never heard of such a thing from any dermatologist or physician. I was raised with cats and dogs.
You have to register before you can post on our site.
Members Images
Join Psoriasis Club
Psoriasis Club is self funded, we don't rely on sponsorship or donations. We offer a safe
friendly forum and are proactive against spammers, trolls, and cyberbullying. Join us here!
No Advertising.
No Corprate Sponsors.
No Requests for Donations.
No Cyber-Bullying.
No Scams or Cures.
No Recruitment Posts.
No promotions or offers.
No Trolls.
No Spam.
Just a small bunch of friendly people with psoriasis sharing information and support.
Forum Statistics
» Members: 981 » Latest member: rphillips812003 » Forum threads: 7,041 » Forum posts: 254,866
There are currently 70 online users. »0 Member(s) | 69 Guest(s) "YOYO" The Psoriasis Club Bot Is On-line
Psoriasis Cure!
How many people have Psoriasis?
In 2012 there were approximately 36.5 million prevalent cases of psoriasis, and by 2022, GlobalData epidemiologists forecast that this figure will reach approximately 40.93 million.
The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world.
The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy.
Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.